[ad_1]
Pfizer Inc. and BioNTech SE’s Covid-19 vaccine remains highly effective six months after its second dose, an indication that protection may last even longer.
The findings, released Thursday, emerged from an ongoing examination of how volunteers in the late-stage gunshot trial were doing and whether they contracted Covid-19 with symptoms.
In the rush to introduce vaccines against a new virus, companies and other vaccine researchers have been unable to determine how long injections would provide protection or whether booster injections would be needed to provide protection.
Pfizer said it hoped to provide more information on protection beyond six months in the coming weeks. The companies said they plan to continue tracking the study subjects for two years. Some vaccines, such as the measles vaccine, provide lifelong immunity, while others, such as the flu vaccine, must be administered annually.
Further analysis suggested that the vaccine worked effectively against a variant first identified in South Africa, Pfizer and BioNTech said. And the companies said they haven’t found any serious security issues so far.
[ad_2]
Source link